Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore
International Journal of Molecular Sciences · 18.09.2025 · 26 (18) · 9100
DOI: 10.3390/ijms26189100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.09.2025. Verfasst von Andrea Camerini und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Cardiovascular Diseases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunotherapy improved survival in a significant number of cancer patients as never before. Its benefits spread across cancer types and stages, and new drugs, new combination, and new indications are on the way. Both atherosclerosis and cancer are associated with the same risk factors, molecular processes, and a persistent inflammatory state that is attributed to immune system dysregulation. Clinicians are now facing a new category of patients that are long survivors/cured by immunotherapy. While short-to-medium-term side effects of immunotherapy are well characterized, long-term exposure to immune checkpoint inhibitors could be associated with new and unpredicted toxicity with a potential impact on survival, reducing the clear advantage of immunotherapy. Because of this, it is clear that the worsening of atherosclerosis emerges as the most relevant long-term side effect, translating into an increased incidence of atherosclerosis-related cardiovascular events, such as myocardial infarction, ischemic stroke, and peripheral artery disease. We review the available evidence of this relevant association, providing an overview for all clinicians involved in the multidisciplinary cancer care process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy.
- Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar di Valpolicella, Italy.
- Cardiology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy.
- UOSD Cardiologia di Interesse Oncologico, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
- Cardiology, "Guglielmo da Saliceto" Hospital, 29121 Piacenza, Italy.
- Cardiology Division, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
ORCID-Profile: Andrea Camerini, Alessandro Inno, Maria Laura Canale, Andrea Tedeschi, Alessandra Greco, Marzia De Biasio, Irma Bisceglia, Luigi Tarantini, Claudio Bilato, Alessandro Navazio
Zitieren
APA
Camerini, A., Inno, A., Canale, M. L., Oliva, S., Tedeschi, A., Greco, A., De Biasio, M., Maurea, N., Bisceglia, I., Tarantini, L., Gallucci, G., Riccio, C., Geraci, G., Bilato, C., Navazio, A., Iacovoni, A., Colivicchi, F., Grimaldi, M., & Oliva, F. (2025). Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore. International Journal of Molecular Sciences, 26(18), 9100. https://doi.org/10.3390/ijms26189100
Vancouver
Camerini A, Inno A, Canale ML, Oliva S, Tedeschi A, Greco A, et al. Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore. International Journal of Molecular Sciences. 2025;26(18):9100. doi:10.3390/ijms26189100
BibTeX
@article{Camerini2025,
author = {Camerini, Andrea and Inno, Alessandro and Canale, Maria Laura and Oliva, Stefano and Tedeschi, Andrea and Greco, Alessandra and De Biasio, Marzia and Maurea, Nicola and Bisceglia, Irma and Tarantini, Luigi and Gallucci, Giuseppina and Riccio, Carmine and Geraci, Giovanna and Bilato, Claudio and Navazio, Alessandro and Iacovoni, Attilio and Colivicchi, Furio and Grimaldi, Massimo and Oliva, Fabrizio},
title = {Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {18},
pages = {9100},
doi = {10.3390/ijms26189100}
}
EUVIMED